MEDCL MedinCell SA

MedinCell launches Regulatory Development of mdc-WWM Program

MONTPELLIER, France--(BUSINESS WIRE)--

MedinCell (Paris:MEDCL) has designed, tested and selected with the support of the Bill & Melinda Gates Foundation the candidate formulation which can now enter preclinical development

  • MedinCell has demonstrated in vivo the feasibility of a contraceptive based on its BEPO® technology, administered by subcutaneous injection, fully bioresorbable and active for six months (mdc-WWM program)
  • The Bill & Melinda Gates Foundation grant of $19 million over four years will fund preclinical activities and an initial clinical study (cf. press release of November 28, 2019)
  • MedinCell owns all commercial rights worldwide, including in the United States, where contraception is a $ 5 billion market
  • It is the sixth product based on MedinCell's BEPO® technology to enter regulatory development

About MedinCell

MedinCell is a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. The BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing over 25 different nationalities.

EN
22/04/2020

Underlying

MEDCLMedinCell SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MedinCell SA

Oscar Haffen Lamm
  • Oscar Haffen Lamm
MEDCL MEDINCELL SA

Medincell: Uzedy TRx shows strong demand, mdc-TJK NDA filing expected ...

Yesterday Teva presented its Q1'25 results, with Uzedy sales for the quarter coming in at USD39m (+160% YoY). While beating Teva's css (USD32.5m, +20%), sales appeared relatively flattish compared Q4 (USD43m), which could be attributed to calendar effects and stock adjustments. We remain optimistic

05/08/25 May 8, 2025 1 EN
Oscar Haffen Lamm
  • Oscar Haffen Lamm
MEDCL MEDINCELL SA

MedinCell and iM4TB to initiate development of a Macozinone LAI in tub...

MedinCell and iM4TB to initiate the development of a LAI version of Macozinone for the treatment of tuberculosis, a potential first-in-class which has shown promising results in past phase 1/2 studies. The value add of a long-acting formulation in tuberculosis is clear, considering that current tre

04/23/25 April 23, 2025 1 EN
Oscar Haffen Lamm
  • Oscar Haffen Lamm
MEDCL MEDINCELL SA

MedinCell: patient and HCP survey highlight key features of its olanza...

Teva presented early clinical feedback from a patient and healthcare professional survey regarding its olanzapine LAI TEV'749 (mdc-TJK), in particular around important schizophrenia treatment factors — dosing schedule, initiation regimen, SC administration, post-injection monitoring requirements an

04/01/25 April 1, 2025 1 EN
 PRESS RELEASE
Free
MEDCL MEDINCELL SA

MedinCell : Information relative au nombre d’actions composant le capi...

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: MedinCell (Paris:MEDCL) : Place de cotation : Euronext Paris, Compartiment B Code ISIN : FR0004065605 Date Nombre de titres composant le capital en circulation Nombre total de droits de vote Total brut (1) Total net (2) 28 février 2025 33 065 845 44 689 724 44 684 224 (1) Le nombre de droits de vote bruts (ou droits de vote “théoriques”) sert de base de calcul pour les franchissements de seuil. Conformément à l’article 223-11 du Règlement Général de l’AMF, ce nombre est calculé sur la base de l’ensembl...

March 7, 2025 1 FR
 PRESS RELEASE
Free
MEDCL MEDINCELL SA

Medincell renforce son Conseil d’administration pour accompagner sa cr...

MONTPELLIER, France--(BUSINESS WIRE)-- Regulatory News: Medincell (Paris:MEDCL): Pascal Touchon rejoint le Conseil d’administration : 40 ans d'expérience internationale dans l'industrie biopharmaceutique à des postes de direction générale et stratégique et en tant que membre de conseils d'administration de sociétés américaines et européennes, Ancien Directeur Mondial de la Stratégie et du Business Development puis de l’activité globale Cell & Gene de Novartis Oncology, il a dirigé le développement et le lancement international de la toute première thérapie cellulaire et génique approuvée...

March 6, 2025 1 FR

ResearchPool Subscriptions

Get the most out of your insights

Get in touch